We are driving innovation with industry and manufacturing partners to transform industries and deliver growth to our economies, thereby helping to improve people’s livelihoods.
We are improving the health of people across the world through new discoveries, treatments and patient pathways and working in partnership to build a transformative health ecosystem in our region.
We are working to understand the impact of climate change on the planet and its people, to improve air quality, and developing new technologies to decarbonise energy and transport in partnership with industry and government.
We are working with our partners to tackle inequalities in all aspects of society, striving to make change for a fairer world and one in which people can enjoy a fulfilling, rewarding life.
We explore what it means to be human – in historical and cultural contexts, within ethical and legal norms and through languages and communication.
From atoms to astronomy, computers to cars and robots to robust materials, our goal is to transform our understanding of the world to make life easier, healthier and more sustainable.
Across the breadth of life and environmental sciences, we discover, apply and translate science to forge major advances in human and environmental health.
With more than 1,000 academic staff researchers and around £80 million new research funding per year, we are dedicated to performing world-leading research with the ultimate goal of improving human health.
We address the challenges facing society and the economy, from shedding light on the refugee crisis, to character education in schools, through to developing leaders in the NHS.
ARISTOCRAT: A randomised controlled phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma
ARISTOCRAT is a UK trial testing the use of the cannabis-based drug Sativex with the current chemotherapy treatment in treating patients with recurrent glioblastoma.
The trial is led by Professor Susan Short (Chief Investigator) at University of Leeds, in collaboration with CRCTU at the University of Birmingham and is funded by The Brain Tumour Charity and sponsored by the University of Birmingham.
When cancer comes back after treatment, doctors call it a recurrence or recurrent cancer. Only patients with recurrent disease are eligible for the ARISTOCRAT trial.
For more information on this, please visit the Cancer Research UK website on why some cancers come back.
Brain tumour patient Baljit Mehat (who sadly passed away this year) previously sat down with the ARISTOCRAT chief investigator, to ask some key questions. This video is for educational purposes only and is not intended to replace patient information for the trial. Patients should speak to a healthcare professional if they want more information about the trial.
Find out more about the trial and how to get involved
Information for hospitals
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating doctor to discuss trials for which they may be eligible.
'Phase II Clinical Trial of Cannabis Derivatives' - The Brain Tumour Charity
'Can we grow the treatments of tomorrow?' - That Cancer Conversation (Cancer Research UK)
'Trial to test if cannabis-based mouth spray can beat brain tumours' - The Guardian (3 August 2021)
'Sativex brain tumour trial fundraising launched' - BBC News England (3 August 2021)
'World-first UK trial to assess whether cannabis-based drug could extend life for thousands with aggressive brain tumours' - University of Birmingham UK (3 August 2021)